On April 14, 2023, P. Roy Vagelos, M.D., Chair of the board of directors (the “ Board”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron” or the “ Company”), notified Regeneron of his decision not to stand for re-election at the 2023 Annual Meeting of Shareholders to be held on June 9, 2023 (the “ 2023 Annual Meeting”). Dr. Vagelos will continue to serve as Chair of the Board for the remainder of his term until the conclusion of the 2023 Annual Meeting. Effective upon the expiration of Dr. Vagelos's term, the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board (in addition to Dr. Schleifer's and Dr. Yancopoulos's continued roles as President and Chief Executive Officer and President and Chief Scientific Officer, respectively) and to designate Christine A. Poon as the Lead Independent Director of the Board.

Dr. Vagelos's decision to not stand for re-election was not caused in whole or in part by a disagreement with Regeneron on any matter relating to Regeneron's operations, policies, or practices.